
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

For the month of October 2018

Commission File Number: 001-35776

ACASTI PHARMA INC.

(Translation of registrant's name into English)

545 Promende du Centropolis

Suite 100

Laval, Québec

Canada H7T 0A3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.'s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACASTI PHARMA INC.

Date: October 23, 2018

By: /s/ Jan D'Alvise
Name: Jan D'Alvise
Title: Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
-----------------------	--------------------

<u>99.1</u>	<u>Press Release dated October 23, 2018</u>
-------------	---

Acasti Pharma Announces Closing of C\$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

LAVAL, Quebec, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the “**Company**” or “**Acasti**”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, is pleased to announce that it has closed its previously announced underwritten public offering (the “**Offering**”) of 21,562,000 Class A Shares of the Company (“**Common Shares**”) at a price of C\$1.28 per Common Share for aggregate gross proceeds to the Company of C\$27,600,000 (including, for certainty, 2,812,500 Common Shares issued pursuant to the exercise in full of the over-allotment option by the Underwriter for gross proceeds of C\$3,600,000) pursuant to an underwriting agreement dated October 4, 2018 with Mackie Research Capital Corporation (the “**Underwriter**”), as sole bookrunner and underwriter.

As previously disclosed, on October 11, 2018, the Company announced the closing of its underwritten public offering in the U.S. at a price to the public of US\$1.00 per Common Share for total gross proceeds of US\$19,090,000.

The net proceeds received from the Offering are intended to be used by the Company for the further development of CaPre and the completion of its TRILOGY Phase 3 clinical program, the planning and initiation of regulatory (NDA) submission activities, the further optimization and scale up of CaPre manufacturing activities, the expansion and maintenance of its intellectual property, the expansion and advancement of business development activities, and general administrative expenses, working capital and capital expenditures.

As consideration for the services rendered by the Underwriter in connection with the Offering, the Company has paid the Underwriter a cash commission equal to 6% of the gross proceeds raised under the Offering.

The Common Shares were issued pursuant to a short form prospectus dated October 15, 2018 filed with the securities regulatory authorities in the provinces of Québec, Ontario, Alberta, Manitoba and British Columbia (the “**Prospectus**”). A copy of the Prospectus is available under the Company’s profile on SEDAR at www.sedar.com. The Common Shares will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an exemption from the registration requirements including to Institutional Accredited Investors pursuant to Regulation D of the United States Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For more information on the Offering and the Company’s intended use of the net proceeds of the Offering, please refer to the Prospectus.

About Acasti

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. CaPre is being evaluated in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. and may expand significantly if omega-3s demonstrate long-term cardiovascular benefits in on-going outcomes studies. Acasti’s strategy is to commercialize CaPre in the U.S. and the company is pursuing partnerships to market CaPre in major countries around the world. For more information, visit www.acastipharma.com.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “**forward-looking statements**”). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements,

which speak only as of the date of this press release. Forward-looking statements in this press release include, but are not limited to, the anticipated use of proceeds, the continued progress of the Company's TRILOGY Phase 3 clinical studies, Acasti's ability to conduct all required clinical and non-clinical trials for CaPre, CaPre's potential to become the "best-in-class" cardiovascular drug for treating severe Hypertriglyceridemia (HTG), and Acasti's ability to fund its continued operations.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Special Note Regarding Forward-Looking Statements" section contained in Acasti's latest annual report on Form 20-F, which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar and on the investor section of Acasti's website at www.acastipharma.com (the "**Annual Report**") and in the "Risk Factors" sections contained in the Prospectus. All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities regulators, including the Annual Report and Acasti's latest management's discussion and analysis.

Neither NASDAQ, the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact:

Jan D'Alvise
Chief Executive Officer
450-686-4555
info@acastipharma.com
www.acastipharma.com

Investor Relations Contact:

Crescendo Communications, LLC
(212) 671-1020
ACST@crescendo-ir.com